Marijuana Stock Movers For April 25, 2024
Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment
Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential
Cara Therapeutics Is Worried About This – Should You Be Worried Too?
Cara Therapeutics: Promising Phase 2/3 Trial Progression Fuels Buy Rating
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.